Isolation and Evaluation of Anticarcinogenic Glucosinolates

抗癌芥子油苷的分离与评价

基本信息

  • 批准号:
    7523682
  • 负责人:
  • 金额:
    $ 35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-07-01 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall goals are to develop plant-derived glucosinolates (GS) for long-term human use as dietary chemoprotectors against cancer and other chronic diseases. GS are a large family of thioglucoside N-hydroxysulfates synthesized by plants from several classes of amino acids. They are very abundant in crucifers (broccoli, cabbage, cauliflower) and are likely to provide the main phytochemical contribution to the chemoprotective properties of these plants. GS are the stable, biologically inactive storage forms of isothiocyanates which are potent inhibitors of tumor development and growth. Bioactivation (conversion) of GS to isothiocyanates is catalyzed by plant cell myrosinase and by the gastrointestinal microflora. Mechanistic understanding of the mode of action of these phytochemicals has advanced greatly. The principal obstacles to progress are now lack of adequate quantities of pure GS for evaluation in cells, animals, and humans, and to control and improve bioavailability. Aim 1 is concerned with developing more efficient methods for isolating and purifying new and already known GS on a progressively larger scale from milligrams to kilograms. With support of this grant, a major advance has been our development of highly efficient continuous, centrifugal, counter-current partition chromatography methods which are easily scalable, and have made possible the production of almost 1 kg of glucoraphanin (the precursor of sulforaphane) and its submission to the NCI RAPID program for clinical development. This aim seeks to expand this novel and highly efficient separation technology for isolation of additional new glucosinolates guided by their biological activities. Aim 2 will evaluate the biological activities of a small number of the most promising candidate GS. Activity testing will include evaluating phase 2 enzyme induction, antioxidant, and anti-inflammatory potencies in cell lines; prevention of mouse skin tumors; and protection of human skin against UV. Proposed studies will also assay the antibiotic activity of GS hydrolysates against Helicobacter pylori (a major causative agent of gastric cancer). Aim 3 will identify individuals with high and low GS to isothiocyanate conversion phenotypes and attempt to discern the factors contributing to these characteristics. Cohorts with stable low conversion phenotypes will be subjected to a variety of dietary modifications, including prebiotic and probiotic interventions, in order to increase conversions and improve the bioavailability of isothiocyanates from GS, and enhance their protective efficacy. This information will advance our development of GS as chemoprotectors and could lead to major health benefits. PUBLIC HEALTH RELEVANCE: The goals of this project are to identify plant components that block the development of cancer and other chronic diseases by boosting our cellular defenses against oxidants, DNA-damaging chemicals, inflammation and radiation. We will isolate these components in adequate quantities for evaluation in animals and humans, and formulate appropriate recommendations to achieve disease risk reduction in humans.
描述(由申请人提供):总体目标是开发植物来源的葡萄糖醇(GS),用于长期人类用作针对癌症和其他慢性疾病的饮食化学保护剂。 GS是一个大型硫葡萄糖苷N-羟基硫酸盐,由几类氨基酸的植物合成。它们在十字花序(西兰花,卷心菜,花椰菜)中非常丰富,并且可能对这些植物的化学保护性能提供主要的植物化学贡献。 GS是异硫氰酸盐的稳定,生物学上不活跃的储存形式,它们是肿瘤发育和生长的有效抑制剂。 GS向异硫氰酸盐的生物活化(转化)由植物细胞霉菌酶和胃肠道菌群催化。对这些植物化学物质的作用方式的机械理解已大大提高。现在,进步的主要障碍是缺乏足够数量的纯GS来评估细胞,动物和人类,无法控制和改善生物利用度。 AIM 1关注的是开发更有效的方法来隔离和净化新的且已知的GS,从毫克到公斤逐渐更大。在支持这笔赠款的支持下,我们的一项重大进步是我们开发了高效的连续,离心,反电流色谱方法,这些方法易于扩展,并且使得生产了将近1 kg的葡萄糖磷酸素(Sulforaphane的前代)及其对NCI快速发展的临床开发计划的产生。该目标旨在扩大这种新颖且高效的分离技术,以隔离其生物学活性引导的其他新葡萄糖醇。 AIM 2将评估少数最有前途的候选GS的生物学活动。活性测试将包括评估2期酶诱导,抗氧化剂和细胞系中的抗炎效果;预防小鼠皮肤肿瘤;保护人皮肤对紫外线的保护。拟议的研究还将分析GS水解酸盐对幽门螺杆菌(胃癌的主要病因)的抗生素活性。 AIM 3将识别出高和低GS的个体来异硫氰酸酯转化表型,并试图辨别造成这些特征的因素。具有稳定的低转化型表型的队列将受到各种饮食修饰,包括益生元和益生菌干预措施,以增加转化率并改善GS的异硫氰酸酯的生物利用度,并提高其保护效率。这些信息将推动我们作为化学保护器的GS发展,并可能带来重大健康益处。公共卫生相关性:该项目的目标是通过促进我们针对氧化剂,减轻DNA的化学物质,炎症和放射的细胞防御措施来确定阻止癌症和其他慢性疾病发展的植物成分。我们将以足够的数量来分离这些组件,以评估动物和人类,并提出适当的建议,以减少人类疾病的风险。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PAUL TALALAY其他文献

PAUL TALALAY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PAUL TALALAY', 18)}}的其他基金

MORINGA LEAF OR SEED EXTRACT
辣木叶或种子提取物
  • 批准号:
    7604638
  • 财政年份:
    2006
  • 资助金额:
    $ 35万
  • 项目类别:
Isolation & Evaluation of Anticarcinogenic Glucosinolate
隔离
  • 批准号:
    6765176
  • 财政年份:
    2002
  • 资助金额:
    $ 35万
  • 项目类别:
Isolation and Evaluation of Anticarcinogenic Glucosinolates
抗癌芥子油苷的分离与评价
  • 批准号:
    8114211
  • 财政年份:
    2002
  • 资助金额:
    $ 35万
  • 项目类别:
Isolation and Evaluation of Anticarcinogenic Glucosinolates
抗癌芥子油苷的分离与评价
  • 批准号:
    7898648
  • 财政年份:
    2002
  • 资助金额:
    $ 35万
  • 项目类别:
Isolation & Evaluation of Anticarcinogenic Glucosinolate
隔离
  • 批准号:
    6895837
  • 财政年份:
    2002
  • 资助金额:
    $ 35万
  • 项目类别:
Isolation & Evaluation of Anticarcinogenic Glucosinolate
隔离
  • 批准号:
    6640295
  • 财政年份:
    2002
  • 资助金额:
    $ 35万
  • 项目类别:
Isolation and Evaluation of Anticarcinogenic Glucosinolates
抗癌芥子油苷的分离与评价
  • 批准号:
    7676011
  • 财政年份:
    2002
  • 资助金额:
    $ 35万
  • 项目类别:
Isolation & Evaluation of Anticarcinogenic Glucosinolate
隔离
  • 批准号:
    6544639
  • 财政年份:
    2002
  • 资助金额:
    $ 35万
  • 项目类别:
MECHANISMS OF PROTECTION AGAINST CANCER BY INDUCTION OF PHASE 2 ENZYMES
通过诱导 2 相酶预防癌症的机制
  • 批准号:
    6300285
  • 财政年份:
    2000
  • 资助金额:
    $ 35万
  • 项目类别:
MECHANISMS OF PROTECTION AGAINST CANCER BY INDUCTION OF PHASE 2 ENZYMES
通过诱导 2 相酶预防癌症的机制
  • 批准号:
    6102351
  • 财政年份:
    1999
  • 资助金额:
    $ 35万
  • 项目类别:

相似国自然基金

氨基酸转运体调控非酒精性脂肪肝的模型建立及机制研究
  • 批准号:
    32371222
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
催化不对称自由基反应合成手性α-氨基酸衍生物
  • 批准号:
    22371216
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
特定肠道菌种在氨基酸调控脂质代谢中的作用与机制研究
  • 批准号:
    82300940
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
肠道菌群紊乱导致支链氨基酸减少调控Th17/Treg平衡相关的肠道免疫炎症在帕金森病中的作用和机制研究
  • 批准号:
    82301621
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
氨基酸调控KDM4A蛋白N-末端乙酰化修饰机制在胃癌化疗敏感性中的作用研究
  • 批准号:
    82373354
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目

相似海外基金

Metabolic reprogramming of endothelial precursor cells in subretinal fibrosis
视网膜下纤维化中内皮前体细胞的代谢重编程
  • 批准号:
    10752924
  • 财政年份:
    2023
  • 资助金额:
    $ 35万
  • 项目类别:
Measurement and Prediction of Endothelial Cross-family Signaling
内皮跨家族信号传导的测量和预测
  • 批准号:
    10689341
  • 财政年份:
    2022
  • 资助金额:
    $ 35万
  • 项目类别:
Targeting autophagy to increase the sensitivity of LKB1-deficient lung tumors to angiogenesis inhibitor
靶向自噬提高 LKB1 缺陷型肺部肿瘤对血管生成抑制剂的敏感性
  • 批准号:
    10669269
  • 财政年份:
    2022
  • 资助金额:
    $ 35万
  • 项目类别:
A two amino acid switch in the anti-angiogenic VEGF165b isoform creates a novel agent for therapeutic angiogenesis in peripheral artery disease
抗血管生成 VEGF165b 亚型中的两个氨基酸开关创造了一种用于治疗外周动脉疾病血管生成的新型药物
  • 批准号:
    10589112
  • 财政年份:
    2019
  • 资助金额:
    $ 35万
  • 项目类别:
Influence of Androgen Deprivation and Tumor Microenvironment on Epigenetic Silencing of Tumor Metastasis Suppressor KISS1 during Prostate Cancer Progression
前列腺癌进展过程中雄激素剥夺和肿瘤微环境对肿瘤转移抑制因子 KISS1 表观遗传沉默的影响
  • 批准号:
    9072642
  • 财政年份:
    2016
  • 资助金额:
    $ 35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了